Your browser doesn't support javascript.
loading
Framework of the strengths and challenges of clinically integrated trials: An expert panel report.
Peters, Anthony E; Jones, W Schuyler; Anderson, Brian; Bramante, Carolyn T; Broedl, Uli; Hornik, Christoph P; Kehoe, Lindsay; Knowlton, Kirk U; Krofah, Esther; Landray, Martin; Locke, Trevan; Patel, Manesh R; Psotka, Mitchell; Rockhold, Frank W; Roessig, Lothar; Rothman, Russell L; Schofield, Lesley; Stockbridge, Norman; Trontell, Anne; Curtis, Lesley H; Tenaerts, Pamela; Hernandez, Adrian F.
Afiliação
  • Peters AE; Division of Cardiology, Department of Medicine, Duke University School of Medicine, Durham, NC.
  • Jones WS; Division of Cardiology, Department of Medicine, Duke University School of Medicine, Durham, NC; Duke Clinical Research Institute, Duke University School of Medicine, Durham, NC.
  • Anderson B; MITRE, Bedford, MA.
  • Bramante CT; Departmentd of Medicine, University of Minnesota Medical School, Minneapolis, MN.
  • Broedl U; Boehringer Ingelheim, Ridgefield, CT.
  • Hornik CP; Duke Clinical Research Institute, Duke University School of Medicine, Durham, NC; Department of Pediatrics, Duke University School of Medicine, Durham, NC.
  • Kehoe L; Duke Clinical Research Institute, Duke University School of Medicine, Durham, NC.
  • Knowlton KU; Intermountain Medical Center Heart Institute, Salt Lake City, UT.
  • Krofah E; Milken Institute, Washington, DC.
  • Landray M; University of Oxford, Oxford, England.
  • Locke T; Margolis Institute for Health Policy, Duke University, Durham, NC.
  • Patel MR; Division of Cardiology, Department of Medicine, Duke University School of Medicine, Durham, NC; Duke Clinical Research Institute, Duke University School of Medicine, Durham, NC.
  • Psotka M; Inova Heart and Vascular Institute, Falls Church, VA.
  • Rockhold FW; Duke Clinical Research Institute, Duke University School of Medicine, Durham, NC; Department of Biostatistics & Bioinformatics, Duke University School of Medicine, Durham, NC.
  • Roessig L; Bayer AG, Wuppertal, Germany.
  • Rothman RL; Vanderbilt University Medical Center, Nashville, TN.
  • Schofield L; Novartis Pharmaceuticals Corporation, East Hanover, NJ.
  • Stockbridge N; Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, MD.
  • Trontell A; Patient-Centered Outcomes Research Institute (PCORI), Washington, DC.
  • Curtis LH; Duke Clinical Research Institute, Duke University School of Medicine, Durham, NC.
  • Tenaerts P; Medable, Palo Alto, CA.
  • Hernandez AF; Division of Cardiology, Department of Medicine, Duke University School of Medicine, Durham, NC; Duke Clinical Research Institute, Duke University School of Medicine, Durham, NC. Electronic address: Adrian.hernandez@duke.edu.
Am Heart J ; 275: 62-73, 2024 Sep.
Article em En | MEDLINE | ID: mdl-38795793
ABSTRACT
The limitations of the explanatory clinical trial framework include the high expense of implementing explanatory trials, restrictive entry criteria for participants, and redundant logistical processes. These limitations can result in slow evidence generation that is not responsive to population health needs, yielding evidence that is not generalizable. Clinically integrated trials, which integrate clinical research into routine care, represent a potential solution to this challenge and an opportunity to support learning health systems. The operational and design features of clinically integrated trials include a focused scope, simplicity in design and requirements, the leveraging of existing data structures, and patient participation in the entire trial process. These features are designed to minimize barriers to participation and trial execution and reduce additional research burdens for participants and clinicians alike. Broad adoption and scalability of clinically integrated trials are dependent, in part, on continuing regulatory, healthcare system, and payer support. This analysis presents a framework of the strengths and challenges of clinically integrated trials and is based on a multidisciplinary expert "Think Tank" panel discussion that included representatives from patient populations, academia, non-profit funding agencies, the U.S. Food and Drug Administration, and industry.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Ensaios Clínicos como Assunto Limite: Humans Idioma: En Revista: Am Heart J Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Nova Caledônia

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Ensaios Clínicos como Assunto Limite: Humans Idioma: En Revista: Am Heart J Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Nova Caledônia